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N”-Acetylation is a major co-translational modifica- 
tion occurring at the a-NH2 group of eukaryotic cyto- 
solic proteins. In order to understand better the speci- 
ficity of N”-acetyltransferase, we used the purified 
enzyme from yeast (Lee, F.-J. S., Lin, L.-W., and Smith 
J. A. (1988) J. Biol. Chem. 263, 14948-14955) and 
synthetic peptides mimicking the NH2 terminus of 
yeast and human proteins. Alcohol dehydrogenase I- 
(l-24) and 8 of the 19 synthetic analogues with sub- 
stitutions at the NH&erminal residue were NU-acetyl- 
ated with varying efficiency. Penultimate amino acid 
substitutions, except. for proline, had little influence on 
N”-acetylation. Substitution of sequences from N”- 
acetylated proteins into the yeast sequences which can- 
not be N”-acetylated demonstrated that not only the 
first 3 NHP-terminal residues but also more carboxyl- 
terminal residues were important for determining the 
specificity of N”-acetyltransferase. Two other peptides 
mimicking yeast mitochondrial cytochrome c oxidase 
(subunit VI) and ATPase inhibitor, which are naturally 
non-acetylated, were efficiently acetylated. In addi- 
tion, recombinant human alcohol dehydrogenase I and 
basic fibroblast growth factor, which are naturally N”- 
acetylated, were not acetylated post-translationally. 
N”-Acetylation is a biologically important co- and post- 
translational modification in prokaryotic and eukaryotic cells 
and is a very common chemical modification of the NH2 
terminus of eukaryotic proteins (reviewed in Tsunasawa and 
Sakiyama, 1984; Driessen et al., 1985). For example, mouse 
L-cells and Ehrlich ascites cells have -80% of their intracel- 
lular soluble protein N”-acetylated (Brown and Roberts, 1976; 
Brown, 1979). It is also suggested that N‘“-acetylation plays a 
role in normal eukaryotic translation and processing (Wold, 
1984) and protects against proteolytic degradation (Jornvall, 
1975; Rubenstein and Deuchler, 1979). N”-Acetylation is 
known to be mediated by at least two N”-acetyltransferases: 
one N”-acetyltransferase (N*AT)’ has broad specificity and 
catalyzes general N*-acetylation (Lee et al., 1988; Kamitani 
et al., 1989) and another N”-acetyltransferase has specificity 
for methionine (M-PAT) (Lee et al., 1990). 
The specificity of N”AT was partially deduced from anal- 
yses of protein sequence data derived from disparate proteins 
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(Jornvall, 1975; Driessen et al., 1985; Flinta et al., 1986). 
Serine and alanine are the NH&erminal residues most fre- 
quently observed in N”-acetylated proteins, and these residues 
together with methionine, glycine, threonine, valine, and as- 
partic acid account for almost all N*-acetylated residues. 
However, not all proteins bearing these residues at their NH2 
termini are acetylated, and the structural features which 
hallmark a protein for N”-acetylation remain unknown. There 
have also been in uiuo studies aimed at determining the 
specificity of N”AT using model proteins (yeast iso-l-cyto- 
chrome c (Tsunasawa et al., 1985), plant thaumatin (Huang 
et al., 1987), and human hemoglobin P-chain (Boissel et al., 
1988)) and their variants. However, there has been disagree- 
ment among these in viva studies regarding the specificity of 
iV”-acetylation. Furthermore, all these studies failed to distin- 
guish among the combined specificities of the various enzymes 
(iv*-AT, M-NOAT, methionine aminopeptidase, and acyl- 
amino acid hydrolase) involved in NHs-terminal protein proc- 
essing. 
The present study was aimed at determining the in vitro 
specificity of purified yeast N”AT using a set of 53 synthetic 
peptides, mimicking the NH, termini of yeast and human 
proteins, and two desacetyl recombinant proteins. The in vitro 
specificity was also compared with the specificities determined 
from protein data analyses and in uiuo studies. 
EXPERIMENTAL PROCEDURES 
Materials-Purified, recombinant proteins, human basic fibroblast 
growth factor (FGF), and human ADH I, expressed in yeast and 
Escherichia coli, respectively, were gifts from Dr. L. S. Cousens 
(Chiron Corporation) and from Professor Hans Jornvall (Karolinska 
Institute), respectively. The recombinant, human basic FGF consisted 
of a neariy equal mikture of the N”-acetylated and non-acetylated 
forms of human basic FGF (Barr et al.. 1988). VHlAcetyl-CoA was 
from Amersham Corp., and unlabeled ace&l-CoA was from P-L 
Biochemicals. SP membrane was from Cuno Inc. Reagents for protein 
synthesis were from Applied Biosystems, except t-butoxycarbonyl 
amino acids were from Peninsula and solvents were from Anachem. 
Reagents and solvents for amino acid analysis and Ready-Solv EP 
scintillation mixture were from Beckman. Reagents for protein se- 
quence analysis were from Applied Biosystems. All other chemicals 
were reagent grade or better. 
Peptide Synthesis-Peptides were synthesized using the t-butoxy- 
carbonyl chemistry and an Applied Biosystems 430A Peptide Syn- 
thesizer and characterized as described previously (Finnegan ef al., 
1986). Protein sequence analyses of the ADH I-(1-24) peptide ana- 
logues were carried out using an Applied Biosystems 470A Protein 
Sequencer (Hewick et al., 1981). 
Purification of Yeast N”-Acetyltransferase and NO-Acetylation As- 
says--The purification of yeast iv”-acetyltransferase and the enzyme 
assays utilizing the various synthetic peptide and recombinant protein 
substrates were performed as described previously (Lee et al., 1988). 
The data were reported as percent activity compared with the level 
of acetylation of a synthetic human adrenocortiotropic hormone 
peptide (ACTH), ACTH-(l-24), used previously as a control peptide 
for assaying for N”-acetyltransferase (Woodford and Dixon, 1979). 
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RESULTS 
N”-Acetylation of ADH I-(1-24) and Its Analogues with 
Substitutions at the NH*-terminal Residue-Human ACTH- 
(l-24), used as a control peptide, and yeast ADH I-(1-24) 
were effectively acetylated in vitro by yeast N-AT (Lee et al., 
1988). As shown in Table I, ADH I-(1-24) and 8 of its 19 
synthetic analogues were N”-acetylated, although the effi- 
ciency of acetylation varied from 9 to 103% (Phe C Met < 
Gly = His = Tyr << Pro = Vale Ser = Thr). 
N”-Acetylation of ADH I-(1-24) and Its Analogues with 
Substitutions at the Penultimate Residue-ADH I-(1-24) and 
18 of the 19 synthetic analogues were N*-acetylated in vitro 
by yeast N”AT (Table I). The efficiency of acetylation varied 
from 81-150% (Trp = Gly C Arg < Asn = Cys = Glu = His 
= Ile = Leu = Lys = Met = Phe = Vale Gln = Ser = Thr = 
Tyr < Ala = Asp). The only analogue which was not acetylated 
by yeast N“AT contained proline. 
N”-Acetylation of Chimeric Synthetic Peptides-A human 
superoxide dismutase peptide, superoxide dismutase-(l-24), 
was shown previously to be effectively acetylated, although 
yeast superoxide dismutase-( l-24) could not be acetylated 
(Lee et al., 1988). As shown in Table II, the progressive 
substitution of residues from the human sequence into the 
yeast sequence gradually increased the efficiency of in vitro 
acetylation of the human-yeast chimeric peptide as 2, 3, and 
6 residues were substituted (14, 54, and 80% of ACTH-(l- 
24), respectively). 
Although yeast enolase-( l-24) was shown previously not to 
be acetylated (Lee et al., 1988), human enolase-(l-24) and 
[Ser’,Ile’]enolase-(l-24) (i.e. a human-yeast chimeric peptide 
in which the two NHz-terminal residues of human enolase 
TABLE I 
Relative activity of yeast acetyltransferase for the N”-acetylation of 
ADH I-(1-24) and substituted analogues 
Substrate Activitv” 
% 
ACTH (human) 100 + 5 (control) 
Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp- 
Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg- 
Arg-Pro-Val-Lys-Val-Tyr-Pro 
Alcohol dehydrogenase I-(1-24) (yeast) 
Ser-Ile-Pro-Glu-Thr-Gln-Lys-Gly-Val- 
Ile-Phe-Tyr-Glu-Ser-His-Gly-Lys- 
Leu-Glu-Tyr-Lys-Asp-Ile-Pro 
102 * 5 
First amino acid substitution Second amino acid substitution 
Substrate Activity Substrate Activity 
% % 
Ala _ _ _ _ _ _ _ 0 -Ala _______ 148 + 10 
Arg _ _ _ _ _ _ _ 0 -Arg _______ 102 f 5 
Asn _ _ _ _ _ _ _ 0 -Asn _--_--_ 116 f 5 
Asp _ _ _ _ _ _ _ 0 _ Asp _ _ _ _ _ _ _ 150 + 11 
cys _ _ - _ _ _ _ 0 - cys _ _ - _ _ - _ 123 f 7 
Gin _ _ _ _ _ _ _ 0 _ Gin _ _ _ _ _ _ _ 125 f 7 
Glu _ _ _ _ _ _ 0 -GlU _______ 111 -+ 6 
Gly _ _ _ _ _ _ _ 23 + 4 _ Gly _ _ _ _ _ _ _ 84 + 5 
His _ _ _ _ _ _ 19 + 3 -His _______ 119 zk 6 
Ile _ - - _ _ - - 0 -J&U _______ 117 + 7 
Le” _ _ - _ _ _ _ 0 - Lys - - - - - - _ 113 f 8 
Lys _ _ - _ _ _ _ 0 -Met _______ 120 + 7 
Met _ _ _ _ _ _ _ 15 + 3 -Phe _______ 110 + 6 
phe _ _ _ _ _ _ _ 9+3 _ pro _ _ - _ _ _ _ 0 
pro _ - - _ _ _ _ 70 -+ 5 -fjer _______ 122 k 7 
Thr _ _ _ _ _ _ _ 103 + 6 -Thr _______ 128 iz 8 
Trp _ - - _ _ _ _ 0 -Trp- --__-_ 81 + 5 
Tyr _ _ _ _ _ _ _ 20 * 3 
Vi1 _ _ - _ _ _ 
-Tvr _______ 129 + 8 
69 f 4 - vi1 _ _ _ _ _ _ _ 110 * 7 
’ Data reported as mean activity + S.D. (n = 3-5). 
replaced those of yeast enolase) were effectively and equiva- 
lently acetylated in vitro by yeast N”AT (Table II). 
[Thr2,Lys3]enolase-( l-24) (yeast), whose 3 NH&erminal 
residues are identical to those of human superoxide dismutase, 
was also acetylated but less efficiently than human superoxide 
dismutase-(l-24) (- 25%) (Table II). 
In contrast, [Ty?]enolase-(1-24) and [Ala3]enolase-(l-24), 
whose first 3 NH*-terminal residues are identical to those of 
acetylated parvalbumins from carp (Driessen et al., 1985) and 
coelacanth (Jauregui-Adell and Pechere, 19’78), respectively, 
were not acetylated in vitro by yeast N”AT (Table II). 
N”-Acetylation of Yeast Mitochondrial Proteins Encoded by 
Nuclear Genes-Cytochrome c oxidase, subunit VI (Gregor 
and Tsugita, 1982), and ATPase inhibitor (Matsubara et al., 
1981) are naturally non-acetylated, nuclear gene-encoded pro- 
teins that are normally synthesized in cytoplasm and trans- 
ported into mitochondria. Surprisingly, these desacetyl-tetra- 
dodecapeptides mimicking their NH, termini were efficiently 
acetylated in vitro by yeast N*AT (Table III). 
N*-Acetylution of Recombinant Human ADH Z and Recom- 
binant Human Basic FGF-Although human ADH I contains 
an NO-acetylated seryl residue, the recombinant protein, as 
expressed in E. coli, was not N”-acetylated (Hoog et al., 1987), 
and N”AT did not acetylate this protein in vitro (data not 
shown). Human basic FGF is found to be NH*-terminally 
blocked and is believed to be N”-acetylated (Barr et al., 1988), 
and, as expressed in yeast, -50% was N*-acetylated. Yeast 
N”AT was unable to acetylate non-acetylated human FGF in 
vitro. 
Comparison of the N”-Acetylution of Synthetic Peptides, 
Mutagenized Model Proteins, and Naturally Occurring Pro- 
teins-Table IV shows which NH*-terminal residues were 
acetylated by purified, yeast N”AT in vitro using synthetic 
peptides (i.e. yeast ADH I-(1-24) and 19 NH*-terminally 
substituted peptide analogues). Table IV also shows which 
residues were N”-acetylated in uiuo by yeast N*AT activities 
(consisting of at least two distinct N”-acetyltransferases (Lee 
et al., 1988, 1990)) using recombinant thaumatin and 19 
variants with NHz-terminal substitutions (Huang et al., 1987) 
and which residues were N”-acetylated by N”AT activities in 
cell-free reticulocyte and wheat germ lysates using human 
recombinant hemoglobin P-chain variants (Boissel et al., 
1988). The data from two computer-based analyses of N”- 
acetylated residues identified in disparate natural proteins 
are also presented (Driessen et al., 1985; Flinta et al., 1986). 
The physical parameters and functional properties of the 
amino acids, including side-chain type, maximum side-chain 
length (Hire1 et al., 1989), radius of gyration (Levitt, 1976), 
mean solvent-accessible surface area (Rose et al., 1985a), and 
N-end rule category (Gonda et al., 1989) are also summarized. 
DISCUSSION 
We utilized purified yeast N”AT (Lee et al., 1988), synthetic 
peptides, mimicking the NH, terminus of ADH I (i.e. a well 
studied NO-acetylated, cytoplasmic protein in yeast (Jornvall, 
1977; Jornvall et al., 1980)), and peptide analogues substituted 
at the NHz-terminal and penultimate residues in order to 
assess the in vitro specificity of yeast N*AT toward ADH I. 
ADH I-( l-24) and 8 of 19 analogues substituted at the first 
amino acid position were acetylated but with differing effi- 
ciencies (Table I). Ser, the natural NHz-terminal residue of 
ADH I, and Thr were effectively and equivalently N”-acety- 
lated (Table I). Other commonly acetylated residues (Pro, 
Val, Gly, Tyr, and Met) were also acetylated but considerably 
less efficiently. The [His’] and [Phe’] analogues of ADH I- 
(l-24) were also acetylated by N”AT (Table I), although N”- 
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TABLE II 
Relative activity of yeast acetyltransferase for the N”-acetylation of superoride dismutase, enolase, and various 
chime& synthetic peptides 
Substrate Activity” 
% 
ACTH-(l-24) 100 f 5 (control) 
Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg- 
Pro-Val-Lys-Vai-Tyr-Pro 
Superoxide dismutase-(l-24) (human) 
Ala-Thr-Lys-Ala-Val-Cys-Val-Leu-Lys-Gly-Asp-Gly-Pro-Val-Gln-Gly-Ser-Ile-Asn- 
Phe-Glu-Gln-Lys-Glu 
Superoxide dismutase-(l-24) (yeast) 
Val-Gln-Ala-Val-Ala-Val-Leu-Lys-Gly-Asp-Ala-Gly-Val-Ser-Gly-Val-Val-Lys-Phe- 
Glu-Gln-Ala-Ser-Glu 
[Ala-‘,Thr’]Superoxide dismutase-(l-24) (yeast) 
Ala-Thr-Gln-Ala-Val-Ala-Val-Leu-Lys-Gly-Asp-Ala-Gly-Val-Ser-Gly-Val-Val-Lys- 
Phe-Glu-Gln-Ala-Ser 
[Ala-‘,Thr’,Lys’]Superoxide dismutase-(l-24) (yeast) 
Ala-Thr-Lys-Ala-Val-Ala-Val-Leu-Lys-Gly-Asp-Ala-Gly-Val-Ser-Gly-Val-Val-Lys- 
Phe-Glu-Gln-Ala-Ser 
[Ala-‘,Thr’,Lys2,Ala3,Val’,Cys5]Superoxide clismutase-(l-24) (yeast) 
Ala-Thr-Lys-Ala-Val-Cys-Val-Leu-Lys-Gly-Asp-Ala-Gly-Val-Ser-Gly-Val-Val-Lys- 
Phe-Glu-Gln-Ala-Ser 
86 f 6 
0 
14 + 4 
54 + 5 
80 f 5 
Enolase-(l-24) (human) 
Ser-Ile-Leu-Lys-Ile-His-Ala-Arg-Glu-Ile-Phe-Asp-Ser-Arg-Gly-Asn-Pro-Thr-Val- 
Glu-Val-Asp-Leu-Phe 
Enolase-(l-24) (yeast) 
Ala-Val-Ser-Lys-Val-Tyr-Ala-Arg-Ser-Val-Tyr-Asp-Ser-Arg-Gly-Asn-Pro-Thr-Val- 
Glu-Val-Glu-Leu-Thr 
[Ser’,Ile*]Enolase-(l-24) (yeast) 
Ser-Ile-Ser-Lys-Val-Tyr-Ala-Arg-Ser-Val-Tyr-Asp-Ser-Arg-Gly-Asn-Pro-Thr-Val- 
Glu-Val-Glu-Leu-Thr 
[Thr2,Lys3]Enolase-(l-24) 
Ala-Thr-Lys-Lys-Val-Tyr-Ala-Arg-Ser-Val-Tyr-Asp-Ser-Arg-Gly-Asn-Pro-Thr- 
Val-Glu-Val-Glu-Leu-Thr 
54 + 5 
0 
60 + 7 
20 + 4 
[Tyr’]Enolase-(l-24) (yeast) 
Ala-Tyr-Ser-Lys-Val-Tyr-Ala-Arg-Ser-Val-Tyr-Asp-Ser-Arg-Gly-Asn-Pro-Thr-Val- 
Glu-Val-Glu-Leu-Thr 
[Ala3]Enolase-(1-24) (yeast) 
Ala-Val-Ala-Lys-Val-Tyr-Ala-Arg-Ser-Val-Tyr-Asp-Ser-Arg-Gly-Asn-Pro-Thr-Val- 
Glu-Val-Glu-Leu-Thr 
a Data reported as mean activity + S.D. (n = 3-5). 
TABLE III 
Relative activity of yeast acetyltransferase for the N”-acetylntion of syntketic peptides mimicking mitochondrial 
moteins 
Substrate Activity” 
% 
ACTH-(1-24) 
Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys- 
Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro 
100 -t 5 (control) 
Cytochrome c oxidase-(l-24) (yeast, mitochondrial, subunit VI) 
Ser-Asp-Ala-His-Asp-Glu-Glu-Thr-Phe-Glu-Glu-Phe-Thr-Ala-Arg- 
Tyr-Glu-Lys-Glu-Phe-Asp-Glu-Ala-Tyr 
ATPase inhibitor (l-24) (yeast, mitochondrial) 
Ser-Glu-Gly-Ser-Thr-Gly-Thr-Pro-Arg-Gly-Ser-Gly-Ser-Glu-Asp-Ser- 
Phe-Val-Lys-Arg-Glu-Arg-Ala-Thr 
60 + 5 
‘I6 + 6 
’ Data reported as mean activity + S.D. (n = 3-5). 
acetylated His and Phe have not previously been identified in 
proteins (Table IV). This lack of previous identification may 
be due to the limited number of N”-acetylated proteins that 
have been identified and characterized. 
N*-Acetylated Met residues are most commonly observed 
in proteins with Asp, Glu, or Asn as the penultimate residue 
(Driessen et al., 1985; Flinta et al., 1986; Arfin and Bradshaw, 
1988), and we recently established that the specificity of yeast 
M-N”AT required these residues (Lee et al., 1990) and that 
N”AT could not transfer an acetyl group to the same sub- 
strates.’ Unexpectedly, N”AT acetylated a methionyl residue 
in the context of a Met-Ile.. . sequence, albeit ineffectively 
(Table I). The ability of N*AT to acetylate Met juxtaposed to 
residues other than Asp, Asn, and Glu agreed with Tsunasawa 
et al. (1985) and Boissel et al. (1988). It remains to be ex- 
plained why there is a duplicity of N”AT action toward Met. 
Inexplicably, the [Ala’] analogue of ADH I-(1-24) (authen- 
ticated by protein sequence analysis (data not shown)) was 
* F.-J. S. Lee, L.-W. Lin, and J. A. Smith, unpublished data. 
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TABLE II 
Relative activity of yeast acetyltransferase for the N”-acetylation of superoride dismutase, enolase, and various 
chime& synthetic peptides 
Substrate Activity” 
% 
ACTH-(l-24) 100 f 5 (control) 
Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg- 
Pro-Val-Lys-Vai-Tyr-Pro 
Superoxide dismutase-(l-24) (human) 
Ala-Thr-Lys-Ala-Val-Cys-Val-Leu-Lys-Gly-Asp-Gly-Pro-Val-Gln-Gly-Ser-Ile-Asn- 
Phe-Glu-Gln-Lys-Glu 
Superoxide dismutase-(l-24) (yeast) 
Val-Gln-Ala-Val-Ala-Val-Leu-Lys-Gly-Asp-Ala-Gly-Val-Ser-Gly-Val-Val-Lys-Phe- 
Glu-Gln-Ala-Ser-Glu 
[Ala-‘,Thr’]Superoxide dismutase-(l-24) (yeast) 
Ala-Thr-Gln-Ala-Val-Ala-Val-Leu-Lys-Gly-Asp-Ala-Gly-Val-Ser-Gly-Val-Val-Lys- 
Phe-Glu-Gln-Ala-Ser 
[Ala-‘,Thr’,Lys’]Superoxide dismutase-(l-24) (yeast) 
Ala-Thr-Lys-Ala-Val-Ala-Val-Leu-Lys-Gly-Asp-Ala-Gly-Val-Ser-Gly-Val-Val-Lys- 
Phe-Glu-Gln-Ala-Ser 
[Ala-‘,Thr’,Lys2,Ala3,Val’,Cys5]Superoxide clismutase-(l-24) (yeast) 
Ala-Thr-Lys-Ala-Val-Cys-Val-Leu-Lys-Gly-Asp-Ala-Gly-Val-Ser-Gly-Val-Val-Lys- 
Phe-Glu-Gln-Ala-Ser 
86 f 6 
0 
14 + 4 
54 + 5 
80 f 5 
Enolase-(l-24) (human) 
Ser-Ile-Leu-Lys-Ile-His-Ala-Arg-Glu-Ile-Phe-Asp-Ser-Arg-Gly-Asn-Pro-Thr-Val- 
Glu-Val-Asp-Leu-Phe 
Enolase-(l-24) (yeast) 
Ala-Val-Ser-Lys-Val-Tyr-Ala-Arg-Ser-Val-Tyr-Asp-Ser-Arg-Gly-Asn-Pro-Thr-Val- 
Glu-Val-Glu-Leu-Thr 
[Ser’,Ile*]Enolase-(l-24) (yeast) 
Ser-Ile-Ser-Lys-Val-Tyr-Ala-Arg-Ser-Val-Tyr-Asp-Ser-Arg-Gly-Asn-Pro-Thr-Val- 
Glu-Val-Glu-Leu-Thr 
[Thr2,Lys3]Enolase-(l-24) 
Ala-Thr-Lys-Lys-Val-Tyr-Ala-Arg-Ser-Val-Tyr-Asp-Ser-Arg-Gly-Asn-Pro-Thr- 
Val-Glu-Val-Glu-Leu-Thr 
54 + 5 
0 
60 + 7 
20 + 4 
[Tyr’]Enolase-(l-24) (yeast) 
Ala-Tyr-Ser-Lys-Val-Tyr-Ala-Arg-Ser-Val-Tyr-Asp-Ser-Arg-Gly-Asn-Pro-Thr-Val- 
Glu-Val-Glu-Leu-Thr 
[Ala3]Enolase-(1-24) (yeast) 
Ala-Val-Ala-Lys-Val-Tyr-Ala-Arg-Ser-Val-Tyr-Asp-Ser-Arg-Gly-Asn-Pro-Thr-Val- 
Glu-Val-Glu-Leu-Thr 
a Data reported as mean activity + S.D. (n = 3-5). 
TABLE III 
Relative activity of yeast acetyltransferase for the N”-acetylntion of syntketic peptides mimicking mitochondrial 
moteins 
Substrate Activity” 
% 
ACTH-(1-24) 
Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys- 
Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro 
100 -t 5 (control) 
Cytochrome c oxidase-(l-24) (yeast, mitochondrial, subunit VI) 
Ser-Asp-Ala-His-Asp-Glu-Glu-Thr-Phe-Glu-Glu-Phe-Thr-Ala-Arg- 
Tyr-Glu-Lys-Glu-Phe-Asp-Glu-Ala-Tyr 
ATPase inhibitor (l-24) (yeast, mitochondrial) 
Ser-Glu-Gly-Ser-Thr-Gly-Thr-Pro-Arg-Gly-Ser-Gly-Ser-Glu-Asp-Ser- 
Phe-Val-Lys-Arg-Glu-Arg-Ala-Thr 
60 + 5 
‘I6 + 6 
’ Data reported as mean activity + S.D. (n = 3-5). 
acetylated His and Phe have not previously been identified in 
proteins (Table IV). This lack of previous identification may 
be due to the limited number of N”-acetylated proteins that 
have been identified and characterized. 
N*-Acetylated Met residues are most commonly observed 
in proteins with Asp, Glu, or Asn as the penultimate residue 
(Driessen et al., 1985; Flinta et al., 1986; Arfin and Bradshaw, 
1988), and we recently established that the specificity of yeast 
M-N”AT required these residues (Lee et al., 1990) and that 
N”AT could not transfer an acetyl group to the same sub- 
strates.’ Unexpectedly, N”AT acetylated a methionyl residue 
in the context of a Met-Ile.. . sequence, albeit ineffectively 
(Table I). The ability of N*AT to acetylate Met juxtaposed to 
residues other than Asp, Asn, and Glu agreed with Tsunasawa 
et al. (1985) and Boissel et al. (1988). It remains to be ex- 
plained why there is a duplicity of N”AT action toward Met. 
Inexplicably, the [Ala’] analogue of ADH I-(1-24) (authen- 
ticated by protein sequence analysis (data not shown)) was 
* F.-J. S. Lee, L.-W. Lin, and J. A. Smith, unpublished data. 
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TABLE IV 
N”-Acetylation of synthetic peptides, mutagenized model proteins, and naturally occurring proteins 
Peptide/protein substrates for 
iV’-acetyltransferases 
IV”-Acetylated amino acid residue 
Reference 
Ala A% ASII ASP Cys Gin GlU GUY His Ile La LYS Met Phe Pro Ser Thr Trp Tyr Val 
Yeast alcohol dehydrogenase I- 
(I-24) and its 19 NH&ermi- 
nally substituted peptide ana- 
logues 
Recombinant plant thaumatin 
and its 19 variants with NH2- 
terminal substitution 
Human hemoglobin p-chain var- 
iants 
Various N”-acetylated proteins 
(118) 
Various cytosolic, N”-acetylated 
eukaryotic proteins (71) 
Side-chain type’ 
Maximum side-chain length (A) 
radius of gyration (A) 
Mean solvent-accessible surface 
area (A*) 
N-end rule category’ 
(-) - - 
+c - - 
+ - - 
+ NDd + 
+ ND ND 
Alk + NH2 
1.51 7.40 3.68 
0.77 2.38 1.45 
+ 
+ 
3.74 
1.43 
- - 
+/- - - 
+ - - 
ND ND + 
ND ND + 
SH NH1 - 
2.83 4.93 4.97 
1.22 1.75 1.77 
31.5 93.8 62.2 60.9 13.9 74.0 72.3 
S’ S’ S”’ S” S” p S” 
+ 
+ 
+ 
+ 
+ 
- 
25.2 
DS 
+ + 
ND ND ND ND ND 
ND ND ND ND ND 
+ Alk + SCH3 Ar 
4.64 3.91 3.90 6.37 5.46 5.10 
1.78 1.56 1.54 2.08 1.80 1.90 
+ 
ND 
+ 
2.40 
1.25 
+b 
+ 
+ 
+ 
+ 
OH 
2.41 
1.08 
+ - 
+ - 
+ - 
+ ND 
+ ND 
OH Ar 
2.54 6.64 
1.24 2.21 
46.7 23.0 29.0 110 30.5 28.7 53.7 44.2 46.0 41.7 
S’ DS S’ S’ DS S’ DS S’ S’ S’ 
+ + This work in 
Table I 
Huang et al. 
(1987) 
+/- 
+ + 
ND + 
Boiseel et al. 
(1988) 
Driessen et al. 
(1986) 
Flinta et al. (1986) 
Ar/OH Alk 
6.43 2.55 
2.13 1.29 
59.1 23.5 
Hire1 et al. (1989) 
Levitt (1976) 
Rose et al. (1985a) 
S’ DS Gonda et al. 
(1989) 
a [Ala’]ADH I-(1-24) was not acetylated by yeast N”-acetyltransferase, although the purified enzyme is capable of NE-acetylating the NH*-terminal alanyl residue of 
human superoxide dismutase-(l-24) (see Table II) and of recombinant human superoxide dismutase protein (Hallewell et al., 1987). 
* NH+rminal residue of yeast alcohol dehydrogenase I. 
’ NH,-terminal residue of recombinant thaumatin expressed in yeast. 
d ND, N”-acetylated residue not detected in any protein of this data base. 
’ Abbreviations: +, positively charged; -, negatively charged; Alk, alkyl; Ar, aromatic; OH, hydroxyl; SH, sulfhydryl; NH*, amide; SCHs, methylated thiol. 
‘Abbreviations: s’, stabilizing residues (x = I (primary), II (secondary), III (tertiary)); DS, destabilizing residues. 
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